晚期肝病中白蛋白应用的利与弊
本文综述人血清白蛋白在晚期肝病中的应用。失代偿期肝硬化患者因肝细胞减少及治疗干预导致血清白蛋白降低,输注人白蛋白溶液对大量放腹水、肝肾综合征或自发性细菌性腹膜炎患者有益,长期使用可能减少新并发症、改善生活质量并可能提供生存获益,但需合理化的剂量、疗程和频率,且存在不良反应风险。
要点
- 人白蛋白溶液对大量放腹水、肝肾综合征或自发性细菌性腹膜炎患者有益。
- 长期白蛋白治疗可能减少失代偿期肝硬化新并发症并改善生活质量。
- 慢加急性肝衰竭中氧化型白蛋白亚型增加,白蛋白透析的作用尚不明确。
核心结论
- 人白蛋白溶液在特定晚期肝病并发症中有益,但需权衡利弊并合理化使用。
研究设计与样本
- 综述,总结人血清白蛋白在晚期肝病中的药理作用、临床证据及不良反应。
主要发现
- 失代偿期肝硬化患者血清白蛋白水平因肝细胞减少及治疗干预而降低。
- 人白蛋白溶液对大量放腹水、肝肾综合征或自发性细菌性腹膜炎患者有益。
- 白蛋白改善免疫细胞功能,减轻晚期肝硬化感染严重程度和风险。
- 长期给药可减少新并发症发生、改善生活质量,并可能提供生存获益。
- 慢加急性肝衰竭中潜在有毒的氧化型白蛋白亚型(如人非巯基白蛋白和亚硝基白蛋白)显著增加。
临床怎么用
- 在大量放腹水、肝肾综合征或自发性细菌性腹膜炎患者中可考虑使用人白蛋白溶液。
- 需根据肝病类型和肝硬化分期合理确定白蛋白剂量、疗程和频率。
- 使用白蛋白时应警惕过敏反应、输血反应、容量负荷过重、抗体形成和凝血异常。
- 考虑成本、可及性及给药条件,倡导审慎使用人白蛋白溶液。
- 慢加急性肝衰竭中白蛋白透析的疗效需进一步研究。
局限性
- 不同肝病和肝硬化阶段的白蛋白治疗剂量、疗程和频率需合理化。
- 慢加急性肝衰竭中白蛋白溶液给药的作用不明确。
- 白蛋白透析去除病理性和功能失调白蛋白形式的获益需额外研究。
- 需要新的白蛋白分子和肝病实践中经济替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human serum albumin is the most abundant plasma protein, and it regulates diverse body functions. In patients with advanced and decompensated cirrhosis, serum albumin levels are low because of a reduction in the hepatocyte mass due to disease per se and multiple therapeutic interventions. Because of their oncotic and nononcotic properties, administration of human albumin solutions (HAS) have been found to be beneficial in patients undergoing large-volume paracentesis or who have hepatorenal syndrome or spontaneous bacterial peritonitis. Albumin also improves the functionality of the immune cells and mitigates the severity and risk of infections in advanced cirrhosis. Its long-term administration can modify the course of decompensated cirrhosis patients by reducing the onset of new complications, improving the quality of life, and probably providing survival benefits. There is, however, a need to rationalize the dose, duration, and frequency of albumin therapy in different liver diseases and stages of cirrhosis. In patients with acute-on-chronic liver failure, potentially toxic oxidized isoforms of albumin increase substantially, especially human nonmercaptalbumin and 2, and nitrosoalbumin. The role of administration of HAS in such patients is unclear. Determining whether removal of the pathological and dysfunctional albumin forms in these patients by "albumin dialysis" is helpful, requires additional studies. Use of albumin is not without adverse events. These mainly include allergic and transfusion reactions, volume overload, antibody formation and coagulation derangements. Considering their cost, limited availability, need for a health care setting for their administration, and potential adverse effects, judicious use of HAS in liver diseases is advocated. There is a need for new albumin molecules and economic alternatives in hepatologic practice.
引用
- Jagdish RK, Maras JS, Sarin SK, et al. Albumin in Advanced Liver Diseases: The Good and Bad of a Drug! Hepatology. 2021. PMID: 33772846. doi:10.1002/hep.31836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。